Clinical Trials Directory

Trials / Completed

CompletedNCT06279715

DFI and Aneuploidies

Evaluation of the Association Between the DNA Fragmentation Index (DFI) and the Frequency of Segmental and Total Aneuploidies

Status
Completed
Phase
Study type
Observational
Enrollment
537 (actual)
Sponsor
Clinique Ovo · Industry
Sex
All
Age
18 Years – 43 Years
Healthy volunteers

Summary

IVF is the most commonly employed form of assisted reproductive technologies (ART) for the 10-15% of couples who face difficulties becoming pregnant. Many individuals elect to have their IVF-derived embryos analyzed using pregenetic implantation testing for aneuploidies (PGT-A). The use of PGT-A is particularly beneficial for patients at higher risk for aneuploidy, such as those of advanced maternal age and those faced with recurrent pregnancy loss or recurrent implantation failure. Segmental aneuploidies are generated when a small piece of a chromosome is gained or lost during cell division, resulting in subchromosomal copy number (CN) changes. The frequency of segmental aneuploidies during the cleavage stage varies between studies, from as low as 3.9% to 15% and up to 70 % with no reported correlation with maternal age. This can be explained by the fact that, unlike whole chromosome aneuploidies, segmental aneuploidies most often involve paternally inherited chromosomes.

Conditions

Interventions

TypeNameDescription
OTHERPreimplantation Genetic Testing for AneuploidyPGT-A typically involves the biopsy of three to eight cells from the developing embryo after approximately five days of culture. This technology also allows for the identification of segmentally aneuploid embryos.

Timeline

Start date
2024-01-19
Primary completion
2024-11-14
Completion
2024-11-14
First posted
2024-02-28
Last updated
2025-07-31

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT06279715. Inclusion in this directory is not an endorsement.